William Dillon, DO
Infectious Disease · Detroit, MINPI 1922456615
Payments from drug & device makers
What this record shows
This record is dominated by education: $454 of the $565 with a category attached, or 80.3%. Astellas Pharma US Inc accounts for 73.2% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $387, 6.2 times the $63 reported in 2023.
Across 8 payments — averaging $70.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$414
- Shionogi Inc$111
- Paratek Pharmaceuticals, Inc.$40
Across 2 payments — averaging $59,658 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$110K
- Astrazeneca UK Limited$9K
What the payments were for
- Food & beverage$11120%
- Education$45480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $414 |
| Shionogi Inc | 1 | $111 |
| Paratek Pharmaceuticals, Inc. | 1 | $40 |
How this compares
$565 in reported general payments places this provider in the 65th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 11 | $23,339 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $567 |
| Doxycycline Hyclate | 17 | $275 |
| Ciprofloxacin Hcl | 13 | $107 |
| Tenofovir Disoproxil Fumarate | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Detroit
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Rodger MacarthurDetroit$150K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Marcus ZervosDetroit$26K
- Jack SobelDetroit$18K
- Smitha GudipatiDetroit$16K
- Ronaldo SupenaDetroit$14K
- Wasif HafeezDetroit$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.